Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

85.7K
Overview
85.7K
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

2.7K
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
2.7K
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

636
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
636

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Pre-Kidney Transplant Blood-Based Next-Generation Sequencing Assay to Predict Early Acute Rejection.

Kidney360·2026
Same author

Longitudinal Changes in the Impact of Socioeconomic Status on Graft Failure in Kidney Transplantation.

Kidney360·2026
Same author

Donor App Increases Awareness and Overall Living Kidney Organ Donation.

Clinical transplantation·2025
Same author

Correction to: Access to robotic assisted kidney transplant for recipients: a systematic review and call for reporting standards.

Journal of robotic surgery·2024
Same author

Psychosocial Evaluation of Living Kidney Donors: A Survey of Current Practices in the United States.

Transplantation·2024
Same author

Access to robotic assisted kidney transplant for recipients: a systematic review and call for reporting standards.

Journal of robotic surgery·2024

Related Experiment Video

Updated: Mar 13, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

17.5K

Immunosuppression Minimization and Avoidance Protocols: When Less Is Not More.

Rohini Prashar1, K K Venkat1

  • 1Division of Nephrology and Transplant Institute, Henry Ford Hospital, Detroit, MI.

Advances in Chronic Kidney Disease
|October 16, 2016
PubMed
Summary

Kidney transplant recipients face suboptimal long-term graft survival. New strategies focus on minimizing immunosuppression, like calcineurin inhibitors (CNIs), to improve outcomes and reduce toxicity.

Keywords:
AvoidanceCalcineurin inhibitors (CNIs)CorticosteroidsImmunosuppressionMinimization

More Related Videos

Murine Model of Epicutaneously-Induced Immunomodulation
09:07

Murine Model of Epicutaneously-Induced Immunomodulation

Published on: June 24, 2025

614
In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
18:48

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

15.0K

Related Experiment Videos

Last Updated: Mar 13, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

17.5K
Murine Model of Epicutaneously-Induced Immunomodulation
09:07

Murine Model of Epicutaneously-Induced Immunomodulation

Published on: June 24, 2025

614
In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
18:48

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

15.0K

Area of Science:

  • Nephrology
  • Transplantation Immunology
  • Pharmacology

Background:

  • Kidney transplantation offers superior survival and quality of life for end-stage kidney disease patients compared to dialysis.
  • Despite advances, long-term kidney allograft survival remains a challenge.
  • Chronic calcineurin inhibitor (CNI) nephrotoxicity and corticosteroid side effects are concerns for long-term graft health.

Purpose of the Study:

  • To review evolving immunosuppression strategies in kidney transplantation.
  • To evaluate approaches aimed at preserving kidney allograft function and minimizing immunosuppression-related adverse effects.
  • To discuss the role of CNI minimization and CNI-free regimens.

Main Methods:

  • Review of current literature on immunosuppressive agents and protocols in kidney transplantation.
  • Discussion of corticosteroid and CNI minimization strategies.
  • Exploration of newer agents like mammalian target of rapamycin inhibitors and belatacept.

Main Results:

  • Minimizing or avoiding corticosteroids and CNIs are key strategies.
  • Replacing CNIs with mTOR inhibitors or using belatacept-based CNI-free regimens are emerging approaches.
  • Recent evidence suggests chronic alloimmune damage, not CNI nephrotoxicity, is the primary cause of late allograft failure.

Conclusions:

  • Optimizing immunosuppression is crucial for long-term kidney allograft survival.
  • CNI minimization protocols need re-evaluation in light of new findings on late allograft failure.
  • Developing safer immunosuppressive regimens remains a priority in kidney transplantation.